BACKGROUND: Both the adaptative and the innate immune systems interplay in multiple sclerosis (MS) pathogeny. Killer-cell immunoglobulin-like receptors (KIRs) are key regulators of the immune response, with activating and inhibitory isoforms. OBJECTIVE: In this study we analysed whether the expression of KIR isoforms is implicated in MS pathogenesis and in the therapeutic response to interferon (IFN)-β. METHODS: Peripheral blood samples were collected from 78 IFN-β-treated MS patients and 46 healthy controls (HC). KIR expression was evaluated by flow cytometry on natural killer (NK) and T cells. RESULTS: The expression of KIRs on NK cells and T lymphocytes did not differ between MS patients and HC. IFN-β therapy decreased the expression of KIR2DL1/2DS1 and increased that of KIR2DL2/3 on NK cells. This therapy also reduced KIR2DL1/2DS1, KIR2DL2/2DL3 and KIR3DL2 expression on CD8(+) T cells. The baseline evaluation of the percentage of circulating CD16(+) NK cells was predictive of the clinical response to IFN-β; however, response to this therapy did not appear related to KIR expression. CONCLUSIONS: This study shows that expression of KIR isoforms on NK and T lymphocytes correlated in different ways with IFN-β therapy, suggesting that KIR dynamics may be associated with the pathways involved in the mechanisms of action of IFN-β.
BACKGROUND: Both the adaptative and the innate immune systems interplay in multiple sclerosis (MS) pathogeny. Killer-cell immunoglobulin-like receptors (KIRs) are key regulators of the immune response, with activating and inhibitory isoforms. OBJECTIVE: In this study we analysed whether the expression of KIR isoforms is implicated in MS pathogenesis and in the therapeutic response to interferon (IFN)-β. METHODS: Peripheral blood samples were collected from 78 IFN-β-treated MSpatients and 46 healthy controls (HC). KIR expression was evaluated by flow cytometry on natural killer (NK) and T cells. RESULTS: The expression of KIRs on NK cells and T lymphocytes did not differ between MSpatients and HC. IFN-β therapy decreased the expression of KIR2DL1/2DS1 and increased that of KIR2DL2/3 on NK cells. This therapy also reduced KIR2DL1/2DS1, KIR2DL2/2DL3 and KIR3DL2 expression on CD8(+) T cells. The baseline evaluation of the percentage of circulating CD16(+) NK cells was predictive of the clinical response to IFN-β; however, response to this therapy did not appear related to KIR expression. CONCLUSIONS: This study shows that expression of KIR isoforms on NK and T lymphocytes correlated in different ways with IFN-β therapy, suggesting that KIR dynamics may be associated with the pathways involved in the mechanisms of action of IFN-β.
Authors: Linrong Lu; Koichi Ikizawa; Dan Hu; Miriam B F Werneck; Kai W Wucherpfennig; Harvey Cantor Journal: Immunity Date: 2007-05 Impact factor: 31.745
Authors: Juan A García-León; María J Pinto-Medel; Lucía García-Trujillo; Carlos López-Gómez; Begoña Oliver-Martos; Isidro Prat-Arrojo; Carmen Marín-Bañasco; Margarita Suardíaz-García; Rafael Maldonado-Sanchez; Oscar Fernández-Fernández; Laura Leyva-Fernández Journal: Mol Immunol Date: 2011-06-12 Impact factor: 4.407
Authors: Charles T Lutz; Anush Karapetyan; Ahmad Al-Attar; Brent J Shelton; Kimberly J Holt; Jason H Tucker; Steven R Presnell Journal: J Immunol Date: 2011-03-14 Impact factor: 5.422
Authors: J E Martínez-Rodríguez; M López-Botet; E Munteis; J Rio; J Roquer; X Montalban; M Comabella Journal: Clin Immunol Date: 2011-09-21 Impact factor: 3.969
Authors: Niklas K Björkström; Peggy Riese; Frank Heuts; Sandra Andersson; Cyril Fauriat; Martin A Ivarsson; Andreas T Björklund; Malin Flodström-Tullberg; Jakob Michaëlsson; Martin E Rottenberg; Carlos A Guzmán; Hans-Gustaf Ljunggren; Karl-Johan Malmberg Journal: Blood Date: 2010-08-09 Impact factor: 22.113